Valrubicin
File:Valrubicin.svg | |
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Protein binding | >99% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C34H36F3NO13 |
Molar mass | 723.644 g/mol |
WikiDoc Resources for Valrubicin |
Articles |
---|
Most recent articles on Valrubicin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Valrubicin at Clinical Trials.gov Clinical Trials on Valrubicin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Valrubicin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Valrubicin Discussion groups on Valrubicin Patient Handouts on Valrubicin Directions to Hospitals Treating Valrubicin Risk calculators and risk factors for Valrubicin
|
Healthcare Provider Resources |
Causes & Risk Factors for Valrubicin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Dosage
800 mg weekly for 6 weeks
Side effects
- Blood in urine
- Incontinence
- painful or difficult urination
- Unusually frequent urination
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Cancer treatments
- Quinones